Elite Athletes Diagnosed and Treated for Diabetes May Reduce Heart Failure

Published Date: 08 Mar 2023

95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.

Read Full News

Latest News

Discussing INTEGUMENT-INFANT and Roflumilast Cream 0.05% in Atopic Dermatitis, With Rocco Serrao, MD

Discussing INTEGUMENT-INFANT and Roflumilast Cream 0.05% in Atopic Dermatitis, With Rocco Serrao, MD

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

AI in Dermatology: Discussing Downsides to the Adoption of Artificial Intelligence

AI in Dermatology: Discussing Downsides to the Adoption of Artificial Intelligence

Potential Causal Relationship Identified Between Depression, Psoriasis

Potential Causal Relationship Identified Between Depression, Psoriasis

Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis

Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis

HS Specialists Express Support for Earlier Use of Biologics Among Patients

HS Specialists Express Support for Earlier Use of Biologics Among Patients

Todays Updates

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Michael Sperling, MD, on AES Lifetime Achievement Award, Evolution in Epilepsy Care Michael R. Sperling, MD, Louie Pasculli

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Thunderstorms Linked to Surge in Asthma ER Visits

Thunderstorms Linked to Surge in Asthma ER Visits

Redefining Transplant Possibilities: The Emergence of Kidney Xenotransplants

Redefining Transplant Possibilities: The Emergence of Kidney Xenotransplants

Febuxostat Lowers Serum Uric Acid More Effectively in Gout Patients With CKD

Febuxostat Lowers Serum Uric Acid More Effectively in Gout Patients With CKD

Todays Updates

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Michael Sperling, MD, on AES Lifetime Achievement Award, Evolution in Epilepsy Care Michael R. Sperling, MD, Louie Pasculli

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Thunderstorms Linked to Surge in Asthma ER Visits

Thunderstorms Linked to Surge in Asthma ER Visits

Redefining Transplant Possibilities: The Emergence of Kidney Xenotransplants

Redefining Transplant Possibilities: The Emergence of Kidney Xenotransplants

Febuxostat Lowers Serum Uric Acid More Effectively in Gout Patients With CKD

Febuxostat Lowers Serum Uric Acid More Effectively in Gout Patients With CKD

Latest News

Discussing INTEGUMENT-INFANT and Roflumilast Cream 0.05% in Atopic Dermatitis, With Rocco Serrao, MD

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

AI in Dermatology: Discussing Downsides to the Adoption of Artificial Intelligence

Potential Causal Relationship Identified Between Depression, Psoriasis

Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis

HS Specialists Express Support for Earlier Use of Biologics Among Patients

News All Time

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Lebrikizumab Benefits AD Patients With Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Lebrikizumab Effectively Treats AD in Patients with Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

The Medical Sisterhood: Balance and Boundaries in the Holiday Season, With Angela Lamb, MD Mona Shahriari, MD, FAAD, Angela Lamb, MD

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

Skin of Color Savvy: Hair-Care Challenges in Dermatology, With Amy McMichael, MD, and Kayla Taylor, MD Amy McMichael, MD, Kayla Taylor, MD

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

Non-Steroidal Topicals: A Game-Changer for Pediatric Atopic Dermatitis, With Emily Becker, MD Emily Becker, MD

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

AI’s Use in Non-Patient-Facing Dermatology Spaces, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

AI’s Use in Non-Patient-Facing Dermatology Spaces, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

Atopic Diseases Significantly Raise the Risk of Post-Surgical Complications

Atopic Diseases Significantly Raise the Risk of Post-Surgical Complications

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD Martina Porter, MD

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD Druhan Howell, MD

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Recommended News For You

Papillary thyroid cancer: New markers offer hope for tailored treatment

Prostate cancer Q&A: Improving detection and reducing overtreatment

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

Nasal therapeutic HPV vaccine could prevent cervical cancer

The hidden costs of cancer for young survivors are derailing their financial futures

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

Recommended Articles For You

How to Prevent Tumor Lysis Syndrome in Cancer Patients 

Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection 

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review 

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control

2.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

3.

New surgical method shows promising results for cervical cancer treatment

4.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

5.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

1.

Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier

2.

Precision to Personalization: Expanding Genetic Testing and Counseling in Oncology

3.

Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models

4.

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers

5.

Improving TIVAP Use: Review of Standardization and Optimization Practices

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part II

2.

Current Scenario of Cancer- Q&A Session to Close the Gap

3.

Navigating the Complexities of Ph Negative ALL - Part VI

4.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

5.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot